Literature DB >> 19364453

Fatigue in Parkinson's disease patients.

Joseph H Friedman1.   

Abstract

Nonmotor features of Parkinson's disease (PD) have only recently been getting the attention they deserve. Dementia, depression, and psychosis are often more devastating than motor dysfunction. Fatigue affects about half of all PD patients and has a major impact on quality of life. Fatigue is the single most important reason cited for medical disability insurance claims by PD patients in the United States. PD patients suffer from both physical and mental fatigue, described as both qualitatively and quantitatively different from the fatigue experienced prior to disease onset. Although fatigue is an early symptom and may be associated with depression, most PD patients with fatigue are not depressed. It is not associated with motor dysfunction but seems to worsen with disease progression. No physiologic differences have been found between fatigued and nonfatigued PD patients. The mechanism of fatigue in PD is unknown. It does not respond to treatment of the motor symptoms. Unlike physical fatigue in normal patients, PD patients often report that their fatigue improves with exercise. No treatment is known to be effective. Methylphenidate was reported to be beneficial in one study, whereas modafinil was not. My own approach to treating fatigue is to look first for other causes that may be treatable, such as sleep dysfunction, depression, or medical disorders. If one is not found, or if it is not treatable, I then institute a course of a low-dose stimulant if there is no cardiac or psychiatric contraindication. I use either amphetamine salts (starting at 10 mg), or methylphenidate (5 mg) taken in the morning and early afternoon, and increased weekly by one dose in the morning or afternoon. Some patients may take their doses unevenly, with more or less for the morning dose. Patients who tend to go to bed late at night may take their doses three times daily.

Entities:  

Year:  2009        PMID: 19364453     DOI: 10.1007/s11940-009-0022-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  26 in total

1.  Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.

Authors:  Dan A Mendonça; Krishe Menezes; Mandar S Jog
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

2.  The Parkinson fatigue scale.

Authors:  R G Brown; A Dittner; L Findley; S C Wessely
Journal:  Parkinsonism Relat Disord       Date:  2005-01       Impact factor: 4.891

3.  Fatigue in levodopa-naive subjects with Parkinson disease.

Authors:  G Schifitto; J H Friedman; D Oakes; L Shulman; C L Comella; K Marek; S Fahn
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

4.  Effects of fatigue on physical activity and function in patients with Parkinson's disease.

Authors:  Carol Ewing Garber; Joseph H Friedman
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

5.  Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Authors:  Charles H Adler; John N Caviness; Joseph G Hentz; Marlene Lind; Judy Tiede
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

6.  Respiratory muscle dysfunction in Parkinson's disease.

Authors:  G E Tzelepis; F D McCool; J H Friedman; F G Hoppin
Journal:  Am Rev Respir Dis       Date:  1988-08

7.  Fatigue in patients with Parkinson's disease.

Authors:  K Karlsen; J P Larsen; E Tandberg; K Jørgensen
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

8.  Fatigue in Parkinson's disease: a nine-year follow-up.

Authors:  J H Friedman; H Friedman
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

9.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

10.  Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Authors:  Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

View more
  5 in total

1.  Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study.

Authors:  Ronald F Pfeiffer
Journal:  Nat Rev Neurol       Date:  2009-10       Impact factor: 42.937

2.  Measurement of patient-centered outcomes in Parkinson's disease: what do patients really want from their treatment?

Authors:  Anne N Nisenzon; Michael E Robinson; Dawn Bowers; Evangelia Banou; Irene Malaty; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2010-10-16       Impact factor: 4.891

Review 3.  Evolving concepts on bradykinesia.

Authors:  Matteo Bologna; Giulia Paparella; Alfonso Fasano; Mark Hallett; Alfredo Berardelli
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

4.  Choosing voluntary exercise over sucrose consumption depends upon dopamine transmission: effects of haloperidol in wild type and adenosine A₂AKO mice.

Authors:  Mercè Correa; Marta Pardo; Pilar Bayarri; Laura López-Cruz; Noemí San Miguel; Olga Valverde; Catherine Ledent; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2015-11-10       Impact factor: 4.530

Review 5.  Effect of rhythmic auditory cueing on parkinsonian gait: A systematic review and meta-analysis.

Authors:  Shashank Ghai; Ishan Ghai; Gerd Schmitz; Alfred O Effenberg
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.